Description

Reliance Industries Limited has listed new Commercial Paper worth Rs. 1,500 crores on BSE Debt segment with redemption dates in December 2025.

Summary

Reliance Industries Limited has listed new Commercial Paper securities totaling Rs. 1,500 crores on the BSE Debt segment on November 18, 2025. The issuance consists of two tranches with face value of Rs. 5 lakhs each, issued on private placement basis with redemption dates in December 2025. Both instruments carry CARE A1+ and CRISIL A1+ ratings.

Key Points

  • Total issuance: Rs. 1,500 crores across two tranches
  • Tranche 1: 5,000 units of Rs. 5 lakhs each (Rs. 250 crores) - Scrip Code 730583, maturing December 29, 2025
  • Tranche 2: 25,000 units of Rs. 5 lakhs each (Rs. 1,250 crores) - Scrip Code 730566, maturing December 24, 2025
  • Credit Rating: CARE A1+ and CRISIL A1+ for both tranches
  • Date of allotment: November 18, 2025
  • Market lot: 1 unit
  • Tick size: 1 paise
  • Trading only in dematerialized form
  • Standard denomination: Rs. 5 lakhs and multiples thereof
  • ICICI Bank Limited is the Issuing and Paying Agent

Regulatory Changes

No regulatory changes introduced.

Compliance Requirements

  • Trading members must trade these securities only in dematerialized form under the specified ISIN numbers
  • Trading shall be conducted in standard denomination of Rs. 5 lakhs and multiples thereof
  • Trading members requiring clarification may contact BSE debt department

Important Dates

  • Allotment Date: November 18, 2025
  • Listing Date: November 18, 2025
  • Redemption Date (Tranche 1): December 29, 2025
  • Redemption Date (Tranche 2): December 24, 2025

Impact Assessment

This is a routine commercial paper listing by Reliance Industries Limited for short-term funding requirements. The listing has minimal market impact as it is a standard debt instrument with short tenure (36-41 days). The high credit ratings (A1+) reflect strong issuer creditworthiness. No impact on equity markets or broader trading operations expected.

Impact Justification

Routine commercial paper listing by blue-chip company with no market-wide implications